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OBJECTIVE—The aim of this study was to determine the
natural history of vascular remodeling of atherosclerotic plaques
in patients with type 2 diabetes and the predictors of vessel
shrinkage.
RESEARCH DESIGN AND METHODS—In this serial intra-
coronary ultrasound (IVUS) study, 237 coronary segments from
45 patients enrolled in the DIABETES I, II, and III trials were
included. Quantitative volumetric IVUS analyses (motorized pull-
backs at 0.5 mm/s) were performed in the same coronary
segment after the index procedure and at the 9-month follow-up.
Nontreated mild lesions (angiographic stenosis 25%) with 0.5
mm plaque thickening and length of 5 mm assessed by IVUS
were included. Vessel shrinkage was deﬁned as a external
elastic membrane area/plaque area  0. Statistical adjustment
by multiple segments and multiple lesions per patient was
performed.
RESULTS—Vessel shrinkage was identiﬁed in 37.1% of seg-
ments and was associated with a signiﬁcant decrease in lumen
area at 9 months (vessel shrinkage, 10  4m m
2 vs. non–vessel
shrinkage, 11  4m m
2; P  0.04). Independent predictors of
vessel shrinkage were insulin requirements (odds ratio 4.6 [95%
CI 1.40–15.10]; P  0.01), glycated hemoglobin (1.5 [1.05–2.10];
P  0.02), apolipoprotein B (0.96 [0.94–0.98]; P  0.001),
hypertension (3.7 [1.40–10.30]; P  0.009), number of diseased
vessels (5.6 [2.50–12.50]; P  0.001), and prior revascularization
(17.5 [6.50–46.90]; P  0.001).
CONCLUSIONS—This serial IVUS study suggests that progres-
sion of coronary artery disease in patients with type 2 diabetes
may be mainly attributed to vessel shrinkage. Besides, vessel
shrinkage is inﬂuenced by insulin requirements and metabolic
control and is associated with more advanced coronary athero-
sclerosis. Diabetes 58:209–214, 2009
C
oronary artery remodeling is a phenomenon by
which vessel dimension changes in response to
atherosclerotic plaque accumulation. This con-
cept was initially described by Glagov et al. (1)
in a postmortem, histopathological study and conﬁrmed
by in vivo studies using intracoronary ultrasound (IVUS)
analysis (2–7). Two different patterns of coronary remod-
eling have been described: a compensatory enlargement of
the vessel in response to an increase of atherosclerotic
plaque (positive remodeling) and a failure to enlarge or
even vessel shrinkage (negative remodeling). The latter is
a common ﬁnding in coronary stenosis of diabetic patients
(8,9). In cross-sectional studies, negative remodeling has
been associated with coronary risk factors, such as hyper-
tension (5) and smoking (4), with the type of plaque (2,7)
(calciﬁed, hard plaques), and with metabolic control in
diabetic patients (10–12). In most studies, remodeling has
been evaluated only at a single time point. Therefore, the
natural history of this process has not been properly
addressed. In addition, remodeling index has been as-
sessed by comparing vessel dimension at target site and
that at the most normal-looking cross-section within 10
mm from the lesion taken as reference segment (2–7).
However, reference segments are rarely disease free (9)
and therefore may be also subject to the remodeling
process. This may be especially true in diabetic patients
(9). Nevertheless, no previous serial IVUS study has shown
the factors associated with coronary remodeling in dia-
betic patients. Therefore, the aim of this study was to
determine the natural history of vascular remodeling of
atherosclerotic plaques in diabetic patients and the pre-
dictors of vessel shrinkage during time.
RESEARCH DESIGN AND METHODS
Study population. Type 2 diabetic patients enrolled in the DIABETES I, II,
and III trials (13–15) in whom IVUS evaluation was performed were included
in this study. The DIABETES I trial was a randomized, multicenter study that
compared the safety and efﬁcacy of sirolimus-eluting stent versus bare metal
stent implantation in 160 type 2 diabetic patients. The DIABETES II and III
trials were registries of 80 consecutive type 2 diabetic patients either treated
with paclitaxel-eluting stent or tacrolimus-eluting stent, respectively. All of
these trials have the same inclusion and exclusion criteria (13–15). In brief,
type 2 diabetic patients treated with either insulin or oral agents at least for 1
month and one or more de novo lesions amenable for percutaneous revascu-
larization were included. Per protocol, IVUS evaluation had to be attempted in
at least one treated lesion both immediately after successful stent implanta-
tion and at the 9-month follow-up. For the purpose of the current serial IVUS
study, nontreated mild lesions (angiographic stenosis 25% by visual assess-
ment) with a plaque thickening at least 0.5 mm and length of 5m ma s
assessed by IVUS were selected. The coronary segment eligible for serial
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DIABETES, VOL. 58, JANUARY 2009 209analysis had to be located at least 10 mm distal or proximal from the
previously stented segment and thus not subject to balloon injury during the
index procedure. We excluded from the analysis those lesions with artifacts
related to IVUS, such as nonuniform rotational distortion. In addition, patients
with multiple balloon inﬂations during complex procedures were also ex-
cluded when doubts remained concerning the exact location of the inﬂated
balloon. Study protocols were approved by the ethics medical committee of
the participating institutions, and all patients gave written informed consent.
IVUS imaging and analysis. IVUS imaging was carried out at the index
procedure and at 9-month follow-up. The probe was placed at least 10 mm
distal from the stent and was retrieved by means of a motorized pullback up to
the aorto-ostial junction. IVUS pullbacks were performed at a constant speed of
0.5 mm/s. In all cases, the IVUS system used was the ClearView console (CVIS,
Sunnyvale, CA) with the Atlantis-Pro 40-MHz catheter (CVIS). From the motor-
ized pullback, angiographically nonsigniﬁcant plaques not related to the treat-
ment site were serially analyzed. Furthermore, because different types of plaques
and different patterns of coronary remodeling may be encountered throughout a
given coronary lesions, each study lesion was divided into three segments for
serial quantitative and qualitative analyses. This serial IVUS analysis was per-
formed by an independent corelab (University of Florida Health Science Center at
Shands Jacksonville, Jacksonville, FL), blinded to the clinical and laboratory data.
The analyses followed a previously described methodology (16). From the
digitized images, lumen, plaque, and external elastic membrane (EEM) areas
were measured at intervals of 0.5 mm in each coronary segment. Mean lumen,
plaque, and EEM areas and changes from baseline to 9-month follow-up were
calculated. In addition, segments were qualitatively categorized into four types:
soft, mixed, ﬁbrous, and calciﬁed following current deﬁnitions (17) with the
agreement of two independent observers.
Deﬁnitions. Serial vascular changes were categorized as vessel shrinkage or
vessel enlargement. Vessel shrinkage was identiﬁed in those lesions in which
a decrease in the mean vessel area was observed during the 9-month
follow-up. It was deﬁned as the ratio of vessel area to atheroma area 0
(18). Conversely, serial vessel enlargement was deﬁned as a ratio 0. The type
of plaque was deﬁned (17) as soft tissue when at least 80% area was
constituted by material showing less echo reﬂectivity than the adventitia, with
an arc of calcium 10°; ﬁbrous plaque when echo reﬂectivity of at least 80%
of the material was as bright as or brighter than the adventitia without
acoustic shadowing; diffuse calciﬁed plaque when it contained material
brighter than adventitia showing acoustic shadowing in 90°; and mixed
when plaque did not match the 80% criterion.
Biochemical parameters. At the index procedure and at the 9-month
follow-up, total serum cholesterol, triglyceride, HDL cholesterol, LDL choles-
terol, apolipoprotein (apo)A, apoB, A1C, and high-sensitivity C-reactive pro-
tein (hs–C-reactive protein) were measured after overnight fasting, following
prespeciﬁed protocol. Serum total cholesterol, triglyceride, and HDL were
measured by automated enzymatic procedures, and serum apoA and apoB
were measured by immunochemical methods. LDL cholesterol was calculated
by Friedewald formula (19): LDL cholesterol  total cholesterol  HDL
cholesterol  (triglyceride/5). All of the lipid proﬁles were assessed at the
central laboratory of our hospital. hs–C-reactive protein levels were measured
from frozen serum samples by immunonephelometry using a commercially
available kit (Beckman Coulter, Fullerton, CA).
Statistical analysis. Statistical analysis was performed by the SPSS 12.0 and
SAS 9.1 version. Quantitative data are presented as means  SD and
qualitative as percentages. To take into account the intraindividual variability
(repeated assessments), all comparisons (univariable and multivariable) were
adjusted by means of a generalized estimating equations (GEE) model
stratifying per patient, lesion, and segments (20). The association between
IVUS measurement and laboratory data was performed by linear regression
analysis to obtain the regression coefﬁcient (B). To evaluate the association
between clinical and laboratory data with vessel shrinkage, a multivariable
logistic regression model was performed. In this analysis, those variables with
P value 0.1 on univariable analysis or clinically relevant were included:
insulin-dependent diabetes, hypertension, previous revascularization, unsta-
ble angina, number of diseased vessels, statin use, ACE inhibitors use,
triglycerides, apoB, and glycated hemoglobin levels. A two-tailed value of P 
0.05 was considered signiﬁcant.
RESULTS
Baseline characteristics. Overall, 244 arteries studied by
IVUS from 222 patients were reviewed (Fig. 1). One
hundred and ninety-two pullbacks were not amenable for
this serial study. Main reasons included absence of lesion
that met inclusion criteria (n  183, 95.3%) and artifacts
related to IVUS (n  4, 2%). Thus, serial IVUS analyses
were available in 79 lesions from 45 patients. From these
lesions, a total of 237 matched atherosclerotic segments
were ﬁnally deﬁned and serially analyzed for a 9-month
period. Baseline clinical and metabolic characteristics of
the overall population are presented in Table 1. Mean
length of the entire lesions were 10.3  4.4 mm, and each
segment measured on average 3.4  1.5 mm. The type of
plaque most frequently observed in each segments was
mixed (39.2%) followed by calciﬁed (31.2%).
Serial quantitative and qualitative IVUS analyses.
Overall, a signiﬁcant increase in EEM (20.3  4.9 vs. 21.4 
4.9; P  0.001), plaque (10.1  3.4 vs. 10.6  3.5, P 
0.001), and lumen (10.1  3.6 vs. 10.7  3.8, P  0.001)
areas were observed during follow-up. There were strong
positive lineal relationships between EEM and lumen
areas and between EEM and plaque areas (Fig. 2). Con-
versely, correlation between lumen and plaque areas was
weak, although it maintained statistical signiﬁcance.
244 IVUS pullbacks
63 IVUS pullbacks
52 pullbacks
ዘ ዘOne lesion (n=33)
ዘTwo lesions (n=14)
ዘThree lesions (n=2)
ዘFour lesions (n=1)
Excluded (n=181)
ዘNo lesion with inclusion criteria (n=174)
ዘNURD (n=3)
ዘIncomplete circumference (n=3)
ዘRing down (n=1)
Baseline
Follow up
Excluded (n=11)
ዘIVUS pullback did not include the lesion (n=9)
ዘStent implantation before follow-up IVUS (n=1)
ዘIncomplete circumference (n=1)
79 lesions
237 Segments
Divided into 3 (proximal, mid, distal)
FIG. 1. Flow chart of the study.
TABLE 1
Baseline characteristics
Clinical characteristics (n  45)
Age (years) 67.4  9.1
Male 35 (77.8)
Type 1 diabetic 13 (28.9)
BMI 29.3  3.9
Hyperlipidemia 29 (64.4)
Hypertension 30 (66.7)
Smoke 26 (57.8)
Peripheral arterial disease 2 (4.4)
Previous myocardial
infarction 19 (42.2)
Previous revascularization 8 (17.8)
Unstable angina 31 (68.9)
Multivessel disease 30 (66.7)
LVEF (%) 66.6  14.1
A1C 7.2  1.4
Subsegments (n  237)
Vessel area 20.3  4.9
Plaque area 10.1  3.4
Lumen area 10.1  3.6
Vessel shrinkage 88 (37.1)
Data are means  SD or n (%). LVEF, left ventricular ejection
fraction.
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identiﬁed in 88 segments (37.1%), whereas some degree of
vessel enlargement was observed in the remaining seg-
ments. At follow-up, vessel shrinkage was associated with
a signiﬁcant decrease in lumen area at 9 months (vessel
shrinkage, 10  4m m
2, vs. non–vessel shrinkage, 11  4
mm
2; P  0.04). These two differential patterns of vascular
remodeling are depicted in Fig. 3. Segments that, on
average, shrank during follow-up presented a signiﬁcant
decrease in mean lumen dimension as a result of mean
EEM reduction. In this scenario, mean plaque area was
also reduced during follow-up. Conversely, segments that,
on average, enlarged presented an increase in the mean
lumen area secondary to an enlargement in both mean
EEM and plaque areas. Factors associated with vessel
shrinkage at the univariable analysis are depicted in Table
2. There were not signiﬁcant differences between the type
of plaque and the development of vessel shrinkage (Table
3). By multivariate analysis, independent predictors of
vessel shrinkage were insulin-dependent diabetes, glycated
hemoglobin, apoB level, hypertension, number of diseased
vessels, and prior revascularization (Fig. 4). Results of this
multivariate analysis remained basically unchanged after
excluding those patients with prior revascularization. In
addition, a signiﬁcant inverse correlation between mean
lumen area at follow-up and glycated hemoglobin levels were
observed: lumen area (mm
2)  13.83–0.39 (glycated hemo-
globin, %)  3.8 intrastate variable.
DISCUSSION
As described by Glagov et al. (1), the coronary vessel
develops an adaptive response (remodeling) to compen-
sate for plaque accumulation. An increase in vessel dimen-
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FIG. 2. A: Relationship between plaque area and EEM area. B: Relationship between lumen area and EEM area. C: Relationship between
plaque area and lumen area.
Baseline study Follow-up study
Mean EEM Area: 22.0 ± 5.4 mm2 p<0.001 Mean EEM Area: 19.6  4.4 mm2
Mean Plaque Area: 10.6 ± 2.8 mm2 p=0.13  Mean Plaque Area: 9.5±
±
2.5 mm2
Mean Lumen Area: 11.4 ± 4.4 mm2 p<0.001 Mean Lumen Area: 10.1± 3.8 mm2
Mean EEM Area: 19.2 ± 4.2 mm2 p<0.001 Mean EEM Area: 22.4 4.9 mm2
Mean Plaque Area: 9.9  ± 3.6 mm2 p=0.003  Mean Plaque Area: 11.3  ± 3.8 mm2
Mean Lumen Area: 9.3 ± 2.7 mm2 p=0.04 Mean Lumen Area: 11.1    ± 3.8 mm2
A
B
±
FIG. 3. Patterns of coronary remodeling. A: Vessel shrinkage (n  88). B: Vessel enlargement (n  149).
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DIABETES, VOL. 58, JANUARY 2009 211sions may be able to accommodate the plaque growth
(vessel enlargement or positive remodeling). However,
this compensatory vascular enlargement has a limit and
lumen dimension may be preserved up to 40% of plaque
accumulation. Beyond that limit, any further increase in
plaque will decrease lumen dimensions. On the other
hand, some plaques lack this adaptive behavior, and vessel
shrinkage (or negative remodeling) appears as the main
contributor to lumen reduction. Previous studies have
shown that type 2 diabetic patients develop more fre-
quently negative remodeling than the general population
(9,10); however, the factors associated with this phenom-
enon were unknown.
This is the ﬁrst report on the natural history of coronary
wall structures from diabetic patients by the use of serial
IVUS evaluation. This study demonstrates a bidirectional
pattern of vascular remodeling in diabetic patients over
time. An overall vascular shrinkage (i.e., EEM, plaque, and
lumen reductions) was shown in more than one-third of
the analyzed plaques. On the other side of the spectrum is
the pattern of overall vascular enlargement (i.e., EEM,
plaque, and lumen increases) observed in the remaining
two-thirds of plaques. Thus, according to our ﬁndings,
vessel shrinkage appeared as the major determinant of
lumen reduction during follow-up in nonsigniﬁcant ste-
notic plaques.
Independent factors associated with vessel shrinkage
included insulin requirements, the association with other
cardiac risk factors, advanced coronary artery disease
(CAD) (i.e., patients with previous revascularization or
with multivessel disease), and the metabolic control.
In our study, only mild, and thus not previously revas-
cularized, stenoses were studied. Of interest, we found a
strong association between vessel shrinkage and previous
revascularization. This revascularization was mainly per-
formed by angioplasty (seven of eight) in different seg-
ments or arteries remote from the studied segment. The
remaining patient underwent prior coronary artery bypass
in another artery. Thus, all analyzed segments were not
affected by competitive ﬂow or even turbulences induced
by the presence of surgical anastomoses proximal to any
studied segment. Both vessel shrinkage and prior revascu-
larization may represent markers of the duration of the
atherosclerotic disease. Vessel shrinkage may appear as a
late event in the development of atherosclerosis as a
consequence of the maturation of atherosclerotic plaque
that consists of a reduction in the lipid content and an
increase in ﬁbrosis and calciﬁcation (2).
At the time of the diagnosis of CAD, the presence of
multivessel disease is a sign of an accelerated atheroscle-
rosis in type 2 diabetic patients. In our study, we have
found a relationship between multivessel disease and
negative remodeling that may have resulted from a com-
mon underlying mechanism: endothelial dysfunction. It is
well-documented that diabetic patients have an impair-
ment of endothelial-dependent relaxation (21,22), and this
TABLE 2
Stratiﬁed univariable analysis
Clinical characteristics
Vessel
shrinkage
Nonvessel
shrinkage P value
Age (years) 66.4  10.7 67.5  8.4 0.35
Male 70 (79.3) 119 (79.7) 0.91
Type 1 diabetic 27 (31) 24 (16) 0.009
BMI 29.1  1.4 29.8  3.9 0.16
Hyperlipidemia 61 (69.3) 98 (65.8) 0.57
Hypertension 67 (76.1) 92 (61.3) 0.02
Smoke 53 (60.2) 100 (67.1) 0.28
Peripheral vasculopathy 2 (2.3) 4 (2.7) 0.84
Previous myocardial infarction 40 (45.5) 56 (37.6) 0.23
Previous revascularization 25 (28.4) 11 (7.4) 0.001
Unstable angina 50 (56.8) 109 (73.2) 0.01
Number of vessels disease 2.2  0.8 1.8  0.7 0.001
LVEF 65.1  15.6 65.8  17.2 0.73
Statin 67 (76.1) 137 (91.9) 0.001
ACE inhibitors 40 (45.5) 104 (69.8) 0.0003
Laboratory test
Total cholesterol (mg/dl) 166.6  40.1 169.2  32.9 0.59
Triglycerides (mg/dl) 124.1  46.6 145.8  64.7 0.008
HDL cholesterol (mg/dl) 43.5  13.9 41.6  10.5 0.26
LDL cholesterol (mg/dl) 97.7  39.2 97.9  34.6 0.95
ApoA (mg/dl) 117.6  30.2 119.9  20.7 0.54
ApoB (mg/dl) 89.6  27.5 97.9  21.3 0.03
A1C (%) 7.7  1.4 7.4  1.3 0.06
hs–C-reactive protein 1.0  1.9 1.0  1.2 0.87
Data are means  SD or n (%). LVEF, left ventricular ejection fraction. *All statistics were calculated with the GEE method stratifying by
patients, vessel, and segment.
TABLE 3
Relationship between baseline type of plaque and the develop-
ment of negative remodeling at follow-up
Vessel
shrinkage
Nonvessel
shrinkage P value
Soft 10 (11.5) 21 (14.0) 0.05
Mixed 36 (41.4) 57 (38.0) 0.05
Fibrose 15 (17.2) 24 (16.0) 0.05
Calciﬁed 26 (29.9) 48 (32.0) 0.05
Data are n (%).
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the dysfunctional endothelium can only offer a poor vaso-
motor response to a local increase in the shear stress
caused by plaque deposition (24). As a result, the diseased
coronary segment may lose the capacity to carry out an
adaptive vascular remodeling (i.e., vessel enlargement)
and to delay the atherosclerotic stenosis formation.
The use of insulin in type 2 diabetic patients is a marker
for disease duration, as well as the presence of multivessel
disease, and previous revascularization. The need for
insulin treatment increases risk of cardiovascular events
in the diabetic population (25). In a previous cross-
sectional study (3), a smaller vessel size, less atheroscle-
rotic plaque burden, and less positive remodeling were
evident in type 1 diabetic patients compared with type 2
diabetic patients. Likewise, the presence of hypertension
was also associated with vascular shrinkage. The associa-
tion between negative remodeling and hypertension has
been described previously in the general population (5).
Hypertension substantially increases the risk of both ma-
crovascular and microvascular complications due to a
synergistic effect in the development of cardiovascular
disease (26). Because hypertension is an extremely com-
mon comorbid condition in diabetes, there is a major need
for careful control of other coronary risk factors in this
high-risk population.
Another important factor associated with atherosclero-
sis progression is the metabolic control. Hyperglycemia is
one of the main mechanisms involved in the development
of complications in diabetic patients. Previous studies
(27–29) demonstrated the association of high glycated
hemoglobin levels with the severity of the CAD and with
poorer outcome after percutaneous coronary angioplasty.
Recently, Anand et al. (30) showed that suboptimal glyce-
mic control is a risk factor for coronary artery calciﬁcation
progression. In this regard, this is the ﬁrst study that
demonstrates an association between glycated hemoglo-
bin levels and vessel shrinkage over time. One mechanism
that may be proposed is the formation of advanced glyca-
tion end products (AGEs) (31,32) during hyperglycemia.
Furthermore, AGEs may be involved in blood vessel
interaction and triggering an inﬂammatory-proliferative
process that may contribute to accelerating atherosclero-
sis. Lipid metabolism is commonly impaired in diabetic
patients. LDL levels had been the traditional lipid measure-
ment in the prediction of cardiac events. Other parame-
ters, such as apoB levels, which reﬂect the concentration
of proatherogenic lipoproteins (VLDL and LDL), may be
used as well. Whether apoB is more predictive of the
development of CAD than LDL levels is controversial.
Ingelsson et al. (33) evidenced that apoB levels and other
traditional lipid measurement were comparable in the
prediction of cardiac events. In our study, the apoB serum
levels were negatively associated with vessel shrinkage.
Although no speciﬁc studies addressed the inﬂuence of
apoB levels on vascular changes, we may compare our
results with those reported with LDL levels. In this regard,
previous studies performed in the general population have
demonstrated an association between a decrease in LDL
levels (after statin treatment) and a decrease in the plaque
and vessel volume during follow-up (34,35). In the present
study, the type of plaque was not associated with the
development of vessel shrinkage. These results are in
agreement with previous static IVUS studies performed in
diabetic patients (10,11). Conversely, other investigations
(2,7) showed inconsistent evidence, which revealed the
relationship between plaque characterization and vessel
remodeling. However, these studies only investigated non-
diabetic patients. Thus, no extrapolation can be performed
from that study to the diabetic population. The relation-
ship between metabolic disorder and atherosclerosis pro-
gression observed in our study stresses the importance of
accurate glycemic, lipid, and blood pressure control in
diabetic patients to prevent them from accelerating CAD.
Study limitations. This is an observational study with
two main limitations: the relatively small number of pa-
tients and the selection bias inherent to IVUS studies. In
this regard, there are two important sources of bias. First,
the arteries or lesions unsuitable for IVUS (very small
vessel or heavily calciﬁed lesions) were excluded. For this
reason, the results cannot be extrapolated to those kinds
of lesions and arteries. Second, we have studied only mild
lesions that are more prone to progress or regress. There-
fore, our ﬁndings cannot be applicable to more severely
stenotic coronary segments that might require immediate
revascularization. In our study, measurement of EEM area
of plaques containing deposits of calcium was obtained by
interpolating the adventitial border, and thus, some inac-
11 0 1 0 0
1.48 (1.05-2.10), p=0.02
0.96 (0.94-0.98), p=0.0009
5.6 (2.56-12.5), p<0.001
3.76 (1.37-10.28), p= 0.009
4.62 (1.4-15.06), p=0.01
0.88 (0.35-2.17), p=0.79
17.48 (6.51-46.98), p<0.001
0.39 (0.12-1.26), p=0.11
Glycated hemoglobin
Apolipoprotein B
Nº of diseased vessel 
Hypertension
Insulin-dependent diabetics
Instable angina
Previous revascularization
Statin
0.1
OR (95% CI),   p value
FIG. 4. Independent predictors of vessel shrinkage. Data in the y-axis are presented on a logarithmic scale. *All statistics were calculated with
the GEE method stratifying by patients, vessel, and segment.
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